Decrease of PARP enzyme activity and phosphorylation of class-IIa HDAC4/5/7 were necessary and sufficient for the synergy observed between SIK2 inhibitors and PARP inhibitors for downregulating cancer cell growth in ovarian and breast cancer cell lines and xenografts. The gene discussed is PARP1; the disease is breast cancer.